News - Licensing

Filter

Current filters:

Licensing

Popular Filters

51 to 75 of 981 results

Bristol-Myers and Incyte sign up to evaluate combo regimen of two immunotherapies

27-05-2014

US pharma major Bristol-Myers Squibb and Incyte Corp have set up a clinical trial collaboration to evaluate…

Bristol-Myers SquibbINCB24360IncyteLicensingnivolumabOncologyPharmaceuticalResearch

MacroGenics and Takeda link up to develop DART for autoimmune disorders

27-05-2014

Privately held US biotech firm MacroGenics and Japan’s largest drugmaker Takeda Pharmaceutical have…

BiotechnologyImmunologicalsLicensingMacroGenicsMGD010Takeda Pharmaceutical

Ligand licenses five programs to Viking Therapeutics

23-05-2014

US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Neurotez licenses Leptin therapeutics to GCA Therapeutics for China

23-05-2014

Privately-held US firm Neurotez has executed an exclusive license agreement covering its Leptin derivatives,…

Asia-PacificChinaGCA TherapeuticsLeptinLicensingNeurologicalNeurotezPharmaceutical

BioRestorative Therapies enters research accord with Pfizer

22-05-2014

US stem-cell therapies developer BioRestorative Therapies has entered into a two-year collaborative research…

BioRestorative TherapiesBiotechnologyLicensingMetabolicsPfizerResearch

Prasco to market authorized generic of NeoProfen Injection

22-05-2014

Privately held US generic drugmaker Prasco Laboratories has entered into a distribution and supply agreement…

GenericsLicensingNeoProfenNeurologicalPrasco LaboratoriesRecordatiUSA

Cardiome out-licenses Aggrastat in select European markets

20-05-2014

Canada-based Cardiome Pharma has signed an agreement with AOP Orphan Pharmaceuticals, headquartered in…

AggrastatAOP OrphanAustriaBrinavessCardio-vascularCardiome PharmaHungaryLicensingPharmaceutical

Servier inks oncology collaboration with Novartis

20-05-2014

French independent drugmaker Laboratories Servier has signed a strategic global collaboration agreement…

LicensingNovartisOncologyPharmaceuticalServier

Novartis in up to $1 billion deal to acquire ex-US rights to Fovista

Novartis in up to $1 billion deal to acquire ex-US rights to Fovista

20-05-2014

Swiss pharma major Novartis has signed a licensing and commercialization agreement with US biotech firm…

BiotechnologyFovistaLicensingNovartisOphthalmicsOphthotech

Reckitt Benckiser in deal with AntiOp for naloxone nasal spray for opioid overdose

19-05-2014

The US unit of UK consumer goods conglomerate Reckitt Benckiser has entered into a definitive agreement…

AntiOpLicensingNaloxoneNeurologicalPharmaceuticalReckitt Benckiser

Aslan Pharma signs agreement with CSL to develop novel therapy for asthma

19-05-2014

Singapore-based Aslan Pharmaceuticals has signed a global license agreement to develop an anti-interleukin…

ASLAN PharmaceuticalsBiotechnologyCSL LimitedCSL334LicensingRespiratory and Pulmonary

Reckitt Benckiser and XenoPort ink licensing deal for arbaclofen placarbil

15-05-2014

Reckitt Benckiser’s US pharma subsidiary and XenoPort have entered into a license agreement pursuant…

arbaclofen placarbilGlobalLicensingNeurologicalPharmaceuticalReckitt BenckiserXenoPort

$25 million milestone for Ardelyx from tenapanor deal with AstraZeneca

15-05-2014

Closely-held US biopharma firm Ardelyx has received a $25 million milestone payment from Anglo-Swedish…

ArdelyxAstraZenecaLicensingNephrology and HepatologyPharmaceuticalResearchtenapanor

GlaxoSmithKline divests rights to Treximet to Pernix for $250 million

15-05-2014

UK pharma giant GlaxoSmithKline will divest all of its rights to migraine drug Treximet (sumatriptan/naproxen…

GlaxoSmithKlineLicensingNeurologicalPernix TherapeuticsPharmaceuticalPozenTreximetUSA

Ligand signs dyslipidemia related diseases accord with AstraZeneca unit

14-05-2014

US drugmaker Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration…

AstraZenecaCardio-vascularLicensingLigand PharmaceuticalsOmthera PharmaceuticalsPharmaceuticalResearch

MedImmune and Incyte to collaborate on immunotherapy

MedImmune and Incyte to collaborate on immunotherapy

14-05-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaBahija JallalIncyteL1LicensingMajorMedImmuneOncologyPharmaceuticalTumorTumorsUKUSA

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

12-05-2014

Japanese drug major Eisai has exercised its option to jointly develop and commercialize its clinical…

Biogen IdecEisaiFycompaGermanyItalyLicensingNeurologicalPharmaceuticalPricingRegulationZebinix

Merck KGaA may look to biosimilars and acquisitions for growth

Merck KGaA may look to biosimilars and acquisitions for growth

12-05-2014

German pharma and chemical major Merck KGaA has said it is planning to invest in innovations to ensure…

BiosimilarsLicensingMerck KGaAMergers & AcquisitionsPharmaceutical

Oxford BioTherapeutics uses Amgen’s Xenomouse antibodies for breast cancer

07-05-2014

UK biotech company Oxford BioTherapeutics has obtained the exclusive global rights to USA-based Amgen’s…

AmgenBiotechnologyImmunoGenLicensingOncologyOxford BioTherapeutics

Grunenthal strengthens pain product portfolio with European rights to etoricoxib

07-05-2014

Family-owned German drugmaker Grunenthal Group today announced the signing of an exclusive promotion…

etoricoxibEuropeGenericsGrunenthalLicensingMerck & CoNeurological

51 to 75 of 981 results

Back to top